HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Guidelines have evolving role in modern cancer care
• Adherence to BRCA testing, counseling recommendations poor in the US
• Ipilimumab approved for melanoma in EU
• Resources for expanding services for hereditary cancer risk assessment Sheri A. Babb, MS, CGC; Ofri Leitner, MS, CGC
• Use children’s feedback on symptoms, adverse events to improve cancer treatment Johanna C. Menard, BSN, RN, CPN; Pamela S. Hinds, PhD, RN, FAAN; Max J. Coppes, MD, PhD, MBA
• Two cases of relapse after allogeneic stem cell transplantation William Wood, MD
• Adding CAD to mammography failed to improve detection rate, prognostic characteristics of invasive disease
• Bevacizumab reduced risk for death and progression, but increased toxicity in NSCLC
• Deferasirox reduced iron burden in adults, children with thalassemia major
• Height may provide insight into how cancers develop
• Higher mammographic density associated with more aggressive tumors, DCIS
• NSAIDs associated with reduced risk for myeloid leukemias in adult women
• OPTIMAL: Erlotinib associated with threefold improvement in PFS for NSCLC
• POG 9404: High-dose methotrexate recommended for children with T-cell ALL
• Radiotherapy showed no negative effect on survival in laryngeal cancer
• Short-term ADT improved OS, disease-specific survival
• Study: Consider HCT for all high-risk AML, ALL
• Study: Immunohistochemical staining of sentinel nodes, bone marrow not clinically warranted in early-stage breast cancer
• The dangers of QTc interval prolongation and medications used for cancer treatment Paul Morales, PharmD